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Abstract Long-term estrogen deprivation treatment for
breast cancer can, in some patients, lead to the activation
of alternate cellular pathways, resulting in the re-
emergence of the disease. This is a distressing scenario
for oncologists and patients, but recent intensive molec-
ular and biochemical studies are beginning to unravel
these pathways, revealing opportunities for new targeted
treatments. Far from making present therapies redundant,
these new discoveries open the door to novel combination
therapies that promise to provide enhanced efﬁcacy or
overcome treatment resistance. Letrozole, one of the most
potent aromatase inhibitors, is the ideal candidate for
combination therapy; indeed, it is one of the most
intensively studied aromatase inhibitors in the evolving
combinatorial setting. Complementary to the use of
combination therapy is the development of molecular
tools to identify patients who will beneﬁt the most from
these new treatments. Microarray gene proﬁling studies,
designed to detect letrozole-responsive targets, are
currently under way to understand how the use of the
drug can be tailored more efﬁciently to speciﬁc patient
needs.
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Introduction
The proliferative, invasive, and metastatic potential of
breast tumors may be largely predetermined at an early
stage in the course of disease, whereas genetic alterations
that accumulate during progression from in situ to meta-
static disease are unpredictable and result in speciﬁc
phenotypic changes and loss of sensitivity to treatments
[1]; for example, although the estrogen receptor-positive
(ER+) phenotype may be largely stable over time [2],
hormone therapy-sensitive breast tumors may develop
resistance and progress to a hormone-independent state [3].
In addition, progression to hormone independence may be
associated with alterations in the expression of other reg-
ulatory genes, such as human epidermal growth factor
receptor 2 (HER2) [4]. In the clinical setting, a quantitative
decrease in ER expression was found in over 900 patients
with primary breast cancer when HER2 was ampliﬁed [5].
Recent advances in translational research studies have
highlighted the complexity of ER signaling, including
differential roles for the ERa and ERb subtypes [6], and
multiple regulatory interactions between steroid hormone,
growth factor, and other tyrosine kinase signaling pathways
[7–10]. Greater understanding of tumor biology is begin-
ning to help physicians to individualize treatment selection
based on clinical, pathologic, molecular, and genetic pro-
ﬁling, and to rationally design novel combinations to
improve efﬁcacy and safety.
This article reviews novel approaches with the more
potent third-generation aromatase inhibitor (AI) letrozole
(Femara
1; Novartis Pharmaceuticals) in combination
strategies with agents targeting other growth factor path-
ways. The review explores the hypothesis that combining
letrozole with speciﬁcally targeted therapies may delay or
overcome endocrine therapy resistance in postmenopausal
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Endocrine therapy resistance
It is well established that breast cancer cells can adapt to
low concentrations of estrogen by becoming hypersensitive
to estradiol [11]. Long-term exposure to tamoxifen induces
hypersensitivity to estradiol [12] and this adaptive change
can result in resistance to endocrine therapy [13]. It has
been postulated that tamoxifen is more susceptible than AIs
to this phenomenon because of its intrinsic agonist prop-
erties [12]. Moreover, it has been suggested that highly
potent AIs are required to block estrogen synthesis when
breast cancer tumors are hypersensitive to small amounts
of estradiol [13].
Recent research has provided a compelling explanation
for the development of resistance [13, 14]. Experiments
using MCF-7 and other breast cancer model systems have
identiﬁed alternative intracellular signaling pathways used
by breast tumors to enhance and activate ER signaling, thus
allowing cells to escape from the inhibitory effects of
endocrine therapies [15, 16]. It has been shown that long-
term estrogen deprivation upregulates ERa and growth
factor signaling pathways such as mitogen-activated pro-
tein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K),
and the mammalian target of rapamycin (mTOR) pathways
[14–19]. Of note, Jeng et al. [15] reported that a speciﬁc
inhibitor of MAPK (PD98059) could block the elevation of
activated MAPK observed in MCF-7 cells exposed to long-
term estrogen deprivation. Furthermore, studies in both
wild-type and long-term estrogen-deprived MCF-7 cells
suggested that mTOR has a key role in breast cancer cell
proliferation and showed that mTOR inhibition by farne-
sylthiosalicylic acid (FTS) can reduce proliferation and
induce apoptosis [19].
Growth factor pathways
The role of nongenomic pathways has been highlighted in
resistance to antiestrogen therapy [20]. Classically, estro-
gens bind to nuclear ER to enhance transcription of genes
important in breast cancer proliferation and survival
(genomic pathway) [21]; however, estrogen may also act
through ER located in or near the cell membrane [22].
Nongenomic actions include activation of various growth
signaling pathways, including MAPK [15]. In addition, ER
may indirectly activate epidermal growth factor receptors
(EGFR) via coactivators, including src, leading to activa-
tion of EGFR [23–25]. Subsequently, dimerization of
activated EGFR with other HER family receptors,
particularly HER2, activates intracellular signaling path-
ways, which in turn may enhance nuclear ER signaling [4],
thus completing a vicious cycle of events. Cross-talk
between ER and HER2 pathways has been implicated in
clinical resistance to tamoxifen [4, 7]. Shou et al. [4]
reported that tamoxifen behaves as an agonist in MCF-7
breast cancer cells that express high levels of the coacti-
vator AIB1 (src3) and HER2, resulting in de novo
resistance. Interestingly, addition of an anti-EGFR tyrso-
sine kinase inhibitor eliminated cross-talk and restored
tamoxifen’s antitumor activity [4].
It has been postulated that AIs may be more effective
than selective estrogen-receptor modulators (SERMs) [26]
because they can block genomic and nongenomic activities
of ER [27]. Elucidation of ER biology and interactions
with growth factor signaling pathways will help to identify
potential therapeutic targets for HR+ breast cancer [4, 28].
Combination therapy
Several strategies to inhibit growth factor signaling and
signal transduction in breast cancer have been tested in the
preclinical setting (see Fig. 1). The humanized monoclonal
antibody trastuzumab speciﬁcally targets the extracellular
domain of HER2 [29, 30]. Ampliﬁcation of HER2 occurs
in approximately 25% of breast tumors and is associated
with more aggressive disease and a poor prognosis [31].
Trastuzumab has been shown to restore sensitivity to
estrogen and tamoxifen in estrogen-independent HER2-
transduced MCF-7 cells [32]. Furthermore, trastuzumab
blocked HER2 heterodimer formation and phosphoryla-
tion, reduced ERK1/2 activity, and strongly inhibited cell
growth in MCF-7 cells overexpressing EGFR and HER2
and resistant to tamoxifen [18]. Of note, synergistic inhi-
bition of the BT474 breast cancer cell line was observed
with trastuzumab and the HER dimerization inhibitor
pertuzumab [33], which targets a different domain of
HER2 [34]. The combination of tamoxifen and trast-
uzumab in ER+, HER2+ BT-474 cells resulted in
synergistic growth inhibition due to the enhancement of
cell accumulation in the G0–G1 phase of the cell cycle, and
a decreased number of cells in S phase [35].
HER signaling pathways can also be targeted by inhib-
iting receptor phosphorylation by intracellular tyrosine
kinases [36]. Geﬁtinib and erlotinib both speciﬁcally
inhibit the EGFR tyrosine kinase and have demonstrated
inhibitory activity in models of hormone-resistant breast
cancer [37, 38]. Interestingly, pretreatment of HER2+,
hormone-resistant MCF-7 cells with geﬁtinib eliminated
the agonist effects of tamoxifen and restored its antitumor
activity [4]. In ER+ breast tumors, targeted therapy with
single-agent geﬁtinib was found to be less effective than
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123endocrine therapy [39]; however, tamoxifen plus geﬁtinib
had greater activity than tamoxifen alone in vivo in hor-
mone-sensitive cells [39]. Data also support the use of
EGFR tyrosine kinase inhibitors in combination with
HER2 antibodies, such as trastuzumab, against breast
tumors that express EGFR and high levels of HER2 [37].
Alternatively, the tyrosine kinase inhibitor lapatinib pro-
vides single-agent targeting of both EGFR and HER2 [40,
41]. Using a panel of 31 human breast tumors, Konecny
et al. [41] showed that response to lapatinib was signiﬁ-
cantly correlated with HER2 expression and its ability to
inhibit HER2, Raf, Akt, and ERK phosphorylation. In vivo
studies showed that lapatinib had a sustained antitumor
effect that was further prolonged by combination with
trastuzumab [41]. Another study showed that the combi-
nation of AEE788 (an EGFR/HER2 tyrosine kinase
inhibitor) with letrozole enhanced antiproliferative effects
of these agents by 20–30% in MCF-7 and ZR75.1 cell lines
and by 60–70% in the BT474 cell line [42]. In a model
system of acquired resistance to letrozole, AEE788 par-
tially restored sensitivity to letrozole, whereas rapamycin
was not effective, suggesting that letrozole resistance and
mTOR activation may not be connected in this model [43].
The authors concluded that inhibition of both HER2-
mediated signaling and mTOR-dependent translation may
restore responsiveness to letrozole in breast cancer refrac-
tory to this AI [43].
Strategies to inhibit downstream signal pathways have
also been developed. Farnesyl transferase inhibitors block
the ﬁrst and most important step in the activation of Ras
signaling pathways [44]. Aberrant function of the Ras
signal transduction pathway is common in breast cancer as
a result of upstream activation via HER2 or EGFR [45].
The farnesyl transferase inhibitor R11577 (tipifarnib) was
found to have antitumor activity against MCF-7 xenografts
[44]. Another interesting therapeutic target is mTOR, a
central regulator of G1 cell cycle protein synthesis, that
precedes commitment to normal cellular replication [46].
Treatment of MCF-7 Arom-1 cells with letrozole and the
mTOR inhibitor RAD001 resulted in a further 50%
reduction in proliferation compared with letrozole alone
[47]. Another set of experiments, developed to test the
hypothesis that Akt kinase confers resistance to endocrine
therapy through suppression of ASK1/JNK pathway,
showed that combining RAD001 with letrozole restored
activation of the ASK/JNK pathway and increased the
sensitivity of MCF-7 cells with constitutively active Akt to
endocrine therapy [48]. Studies have also targeted the
selective estrogen receptor down-regulator (SERD) fulve-
strant, which indirectly inhibits growth factor pathways by
down-regulating ER [3]. In MCF-7Ca xenografts, com-
bined treatment with fulvestrant and letrozole prevented
increases in HER2 and activation of MAPK and inhibited
tumor growth [49].
These preclinical models (see Table 1) suggest that
treatments to reduce growth factor signaling pathways may
be useful in the treatment of human breast cancer [52].
Speciﬁcally, novel combination strategies may be
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Fig. 1 Cross-talk between signal transduction pathways and ER
signaling in endocrine resistant breast cancer, with opportunities for
targeted intervention. Estrogen (E2)-liganded ER activates E2-
regulated genes in classical pathway (thick black arrow), but
following long-term tamoxifen therapy resistance can develop with
bidirectional cross-talk (gray arrows) between ER and growth factor
receptors, with association of membrane bound ER with growth factor
receptors, and/or IGFR or EGFR/HER2 activation of ER phosphor-
ylation. Stars show various targeted therapies. AI aromatase inhibitor,
SERD selective estrogen receptor down-regulator, MoAb monoclonal
antibodies, TKI tyrosine kinase inhibitor, FTI farnesyltransferase
inhibitor, CCI cell cycle inhibitor. Reprinted from [28] with
permission from the American Association for Cancer Research
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123developed to prevent or delay the development of endo-
crine therapy resistance [3, 39], to restore sensitivity to
endocrine therapy [53], and to treat hormone-resistant
tumors [18, 46]. Anti-vascular endothelial growth factor
(VEGF) therapy with bevacizumab may be able to over-
come resistance to endocrine therapy and improve efﬁcacy
in HR+ metastatic breast cancer [54], and preclinical
models have shown that the estrogen-induced increase in
VEGF expression may be counteracted by aromatase
inhibition. Inhibition of growth factor signaling and
angiogenesis pathways may be rationally combined with
conventional endocrine strategies for breast cancer [4, 35,
50, 55, 56].
The activity of inhibitors of growth factor signaling
depends on the presence of speciﬁc cellular aberrations,
such as overexpression of HER2 [57] or mutations of
EGFR [58]. Consequently, targeted therapies may have
limitations as single agents because the target is active in a
restricted subset of patients, and breast tumors may
undergo adaptive changes to render the target redundant.
Since tamoxifen exhibits agonist effects on breast cancer
cells exposed to long-term estrogen deprivation [12], it
may be better to combine AIs with inhibitors of growth
factor signaling. Letrozole is one of the most potent AIs
and is one of the most extensively studied AIs in combi-
nation with new agents (see Table 1).
Clinical trials of letrozole in combination with
inhibitors of growth factor signaling pathways
Based on results from preclinical studies, several clinical
trials of novel combinations are under way, with the aim of
improving efﬁcacy and safety of endocrine therapy with
letrozole (see Table 2). Many of these trials are being
conducted in patients with locally advanced or metastatic
breast cancer who have failed prior tamoxifen or have a
suboptimal response to letrozole. This represents a high-
risk, difﬁcult-to-treat population who are candidates for
cytotoxic chemotherapy. Preliminary results have shown
that letrozole can be safely combined with trastuzumab,
lapatinib, everolimus, tipifarnib, bevacizumab, and imati-
nib. It is too early, however, to make deﬁnitive conclusions
about efﬁcacy and clinical beneﬁts with these novel
combinations.
In a clinical trial [69] designed to test whether combi-
nation therapy with letrozole and bevacizumab was
possible, patients with ER+ or progesterone receptor-
positive (PR+) metastatic or locally advanced breast cancer
were treated with letrozole (2.5 mg daily) and bev-
acizumab (15 mg/kg IV every 3 weeks) [54]. The majority
of patients had received prior therapy with a nonsteroidal
AI. The combination of bevacizumab and letrozole was
found to be well-tolerated. Common drug-related toxicities
reported were hypertension, fatigue, headache, and joint
pain. Median progression-free survival was reported to be
10 months, and this compares favorably with the published
data on median time to progression with ﬁrst-line letrozole
(9.4 months) [70]. However, analysis of efﬁcacy and bio-
marker data was confounded by the long duration of
prestudy aromatase inhibition [54, 71]. Nevertheless, when
the data were corrected for duration of previous AI therapy,
the study did determine that changes in circulating endo-
thelial cell (CEC) levels may be a biomarker of response or
progression on anti-angiogenic therapy [71]. Based on
these ﬁndings, a randomized, double-blind, placebo-con-
trolled trial of bevacizumab combined with endocrine
therapy in patients with ER+ or PR+ metastatic breast
cancer has been initiated by the Cancer and Leukemia
Group B (CALGB) (see Fig. 2)[ 54]. The primary end
point of the trial is progression-free survival.
Letrozole plus trastuzumab produced durable responses
in about one in four patients with ER/PR+, HER2+ meta-
static breast cancer, but early progression occurred in one
Table 1 Summary of letrozole in combination with growth factor signaling inhibitors in preclinical models
Target for growth
factor inhibitor
Combination regimen Summary of key ﬁndings References
EGFR/HER2 Letrozole + AEE78 Combination enhanced antiproliferative effects in MCF-7 (ER+ HER2–),
ZR75.1 (ER+ HER2+), and BT474 (ER+ HER2+) cell lines
[42]
Partial restoration of growth inhibitory effects of letrozole in refractory cell lines
(LTLT-Ca; long-term letrozole treated)
[43]
mTOR Letrozole + RAD001
(everolimus)
Letrozole + RAD001 signiﬁcantly increased apoptosis compared with either
agent alone
[50]
Co-treatment increased sensitivity to letrozole in resistant MCF-7 cells with
constitutively active Akt
[48]
RAD001 increased antiproliferative effects of letrozole in MCF-7 Arom 1 cell line [47]
IGFBP Letrozole + rhIGFBP-3 rhIGFBP-3 Enhanced letrozole activity in MCF-7-Ca cells in vitro and in vivo [51]
rhIGFBP recombinant human insulin-like growth factor binding protein
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123in two patients [59]. This suggests that common resistance
pathways may be responsible for relapse [59]. Targeting
multiple pathways may reduce the risk of resistance. The
combination of letrozole and the dual EGFR/HER2 inhib-
itor lapatinib was found to be feasible and well-tolerated in
a phase I study [60], and this regimen is currently being
compared with letrozole plus placebo in a phase III study in
women with ER/PR+ advanced or metastatic breast cancer
[61] (see Fig. 3). Future studies will focus on ﬁnding the
right combination or sequence of agents for different
patients in speciﬁc treatment settings. Furthermore, studies
in the neoadjuvant setting in patients with locally advanced
breast cancer will allow correlative biomarker assessment,
such as the proliferation marker Ki-67, to determine the
efﬁcacy of combination therapies. For example, everolimus
and letrozole are being studied as preoperative therapy of
Table 2 Clinical studies of letrozole and inhibitors of growth factor signaling pathways
Target for growth
factor inhibitor
Combination regimen Study type and patient population Summary of key ﬁndings References
HER2 Letrozole + trastuzumab Phase II
Metastatic BC, postmenopausal,
ER+ and/or PR+, HER2+ (n = 31)
ORR 26%; median TTP 5.8 months [59]
EGFR/HER2 Letrozole + lapatinib Phase I
Advanced BC (ER+ or PR+) or other
tumors (n = 36)
Letrozole + lapatinib safely combined
at recommended single agent
doses
[60]
Phase III
Advanced/metastatic BC (n = 1,200
target accrual)
Ongoing trial; primary end point TTP [61]
mTOR Letrozole + RAD-001
(everolimus)
Phase Ib
Advanced BC pts with suboptimal
response to letrozole (n =6 )
RAD001 pharmacokinetics not altered
by letrozole
[62]
Phase II
Presurgical therapy in patients with
newly diagnosed ER+ BC (n = 255
planned)
Ongoing trial of efﬁcacy and
biomarkers
[63]
Letrozole + CCI-779
(temsirolimus)
Phase II
Advanced or metastatic BC (n = 92)
No difference in ORR, but trend to
longer PFS with
letrozole + temsirolimus (30 mg)
[64]
Phase III
Advanced or metastatic breast cancer
(n = 1,236 planned)
Terminated [65]
Farnesyl transferase Letrozole + tipifarnib Randomized phase II
Advanced or metastatic BC that has
progressed on tamoxifen (n = 121)
ORR 38% for letrozole and 26% for
letrozole + tipifarnib (NS)
[66]
Randomized, placebo-controlled
phase II
Advanced or metastatic BC that has
progressed on antiestrogen therapy
(n = 120)
No longer recruiting [67]
VEGF Letrozole + bevacizumab
(anti-VEGF monoclonal
antibody)
Phase II
Metastatic BC, postmenopausal,
candidates for AI (n = 28)
Letrozole + bevacizumab is
well-tolerated
[54]
Endocrine therapy
(tamoxifen or aromatase
inhibitor) + bevacizumab
Phase III placebo-controlled
First-line therapy in ER+/PR+
Metastatic BC (n = TBC)
Planned trial Planned
CALGB
trial [54]
Bcr-abl Letrozole + imatinib Phase II
Metastatic BC, postmenopausal
ER+ and/or PR+ (n = 15)
Letrozole + imatinib is feasible [68]
BC breast cancer, ORR overall response rate, TTP time to progression, PFS progression-free survival, AI aromatase inhibitor, TBC to be
conﬁrmed
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123primary breast cancer in postmenopausal women [63]. In
this phase II trial, patients are randomized to receive le-
trozole in combination with everolimus or placebo, an
adaptive design strategy, so that identiﬁcation of biomar-
kers can be used to optimize patient selection for a future
phase III trial of ﬁrst-line combination therapy in patients
with advanced breast cancer. Even if a biomarker is not
identiﬁed, the trial is adequately powered to demonstrate a
statistically signiﬁcant difference in treatment effect of the
combination in the overall population.
Combination strategies may also change the conven-
tional approach for treatment selection based on HR status.
Interestingly, it has been suggested that treatment of
HER2+, ER– metastatic breast cancer with trastuzumab
may transform the tumor phenotype to become hormone
responsive [72]. The hypothesis-generating study found
that three of ten patients demonstrated ER overexpression
at 9, 12, and 37 weeks, respectively, following the initia-
tion of trastuzumab. Two of these patients were
subsequently treated with endocrine therapy alone and one
received letrozole for 3 years without evidence of pro-
gression. Further trials of letrozole used in combination
with trastuzumab or sequentially in patients with HER2+,
ER– tumors appear warranted.
Microarray/gene proﬁling studies and optimization of
treatment with letrozole
The growing importance of biomarkers in oncology has
been reﬂected in the US Food and Drug Administration
(FDA), the National Cancer Institute (NCI), and the Cen-
ters for Medicare and Medicaid Services (CMS) Oncology
Biomarker Qualiﬁcation Initiative (OBQI), designed to
improve the development of cancer therapies and the out-
comes for cancer patients through biomarker development
and evaluation [73]. Not only are biomarkers potentially
useful as prognostic and predictive factors but they also
serve as surrogate end points for long-term outcomes. For
example, Dowsett et al. found that changes in Ki-67 in the
neoadjuvant setting may be used to predict likely beneﬁt
(improved disease-free and overall survival) of AIs in the
adjuvant setting [74], potentially expediting clinical
development. Therefore, identifying biomarkers that pre-
dict endocrine resistance is essential for the optimal use of
letrozole. In addition, biomarker studies that help to
delineate the oncogenic pathways may be particularly
useful for the development of novel combination therapies
with letrozole.
Gene expression analysis of tumors represents a novel
approach for biomarker development that promises to
increase the understanding of breast cancer heterogeneity
and facilitate the development of individualized treatment
strategies. Microarray analysis, such as the Affymetrix
Human Genome Gene Chips, is an exciting development in
breast cancer diagnostics that allows the expression of
genes in tumors to be quantiﬁed using RNA retrieved from
breast cancer biopsies. Using cDNA microarray and
unsupervised clustering analysis, ER+ breast cancer can be
subdivided into at least two subtypes, luminal A and
luminal B, with distinct gene expression patterns and
clinical outcomes [75–77]. Supervised analysis, comparing
gene expression patterns between tumors that relapsed and
those that did not, generated a ‘‘gene signature’’ as an
independent prognostic parameter for lymph-node negative
disease [78, 79]. The National Surgical Adjuvant Breast
and Bowel Project (NSABP) has developed a multigene
proﬁling assay, using reverse transcriptase polymerase
chain reaction (RT-PCR) to quantify the expression of 21
genes [80]. The 21-gene assay (Oncotype DX, Genomic
Health) can predict risk of recurrence in patients with HR+
early breast cancer receiving tamoxifen [80, 81] or che-
motherapy [82]. Naderi et al. [83] have also reported
validation of gene expression signatures that may have
predictive value in the clinic. Furthermore, newly identiﬁed
Hormone receptor-positive
postmenopausal women
with metastatic breast cancer
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Letrozole
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Fig. 3 Letrozole and lapatinib phase III trial design. Target recruit-
ment: 1,280 patients
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Endocrine therapy + bevacizumab
(15 mg/kg IV Q3wk)
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Fig. 2 Planned CALGB trial of ﬁrst-line endocrine therapy (tamo-
xifen or aromatase inhibitor) with or without bevacizumab
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123interactions between ER and other signaling pathways have
been studied using microarray analysis [84, 85]. For
example, Bex1 and Bex2 genes have been identiﬁed as
novel breast cancer-related genes and identify a subtype of
ER+ tumors associated with estrogen response and nuclear
factor kappa B (NF-jB) pathways [84]. Advances in gene
proﬁling will provide further insights into tumor biology
and improve prediction of likely response to speciﬁc
therapies in the clinic.
Microarray analysis has shown to be valuable in pre-
dicting response to neoadjuvant endocrine therapy and was
used in a study of neoadjuvant letrozole 2.5 mg/day
administered to postmenopausal women with large oper-
able or locally advanced breast cancers for 3 months [86,
87]. Changes in patterns of gene expression were assessed
from tissue samples taken at diagnosis, 14 days, and
3 months (N = 58). Changes in gene expression level with
treatment were identiﬁed as early as 14 days and involved
classical markers of estrogen action (trefoil factors 1 and
3, LIV-1, KIAA0101) as well as tumor proliferation (cy-
clin D1, cyclin B2, CSK2, cell division cycle 2). The
objective clinical response to neoadjuvant letrozole was
71% (N = 52 assessable). Of note, the observed changes
in gene expression, when clustered, were predictive of
response in all cases except one, whereas classical markers
of estrogen action were not predictive [87]. In another
study, postmenopausal women with primary operable
breast cancer were randomized to 2 weeks of presurgical
treatment with letrozole 2.5 mg/day or anastrozole 1 mg/
day [88]. Microarray gene expression proﬁling (Break-
through Centre cDNA chips) of biopsies taken before and
during treatment identiﬁed differences in gene expression
patterns between the two AIs, although the clinical sig-
niﬁcance of these preliminary ﬁndings remains to be
clariﬁed. Itoh et al. [89] also found differences between
letrozole, anastrozole, and tamoxifen using microarray
analysis on MCF-7 cells stably transfected with the aro-
matase gene (MCF-7Aro). Gene expression patterns
revealed a high correlation between the AIs (letrozole and
anastrozole) and a clear difference between AIs and
tamoxifen [89].
Emerging data therefore suggest that estrogen-respon-
sive genes are candidate biomarkers [90] and may be useful
in the clinic as predictive factors of beneﬁt from AI treat-
ment [89]. The value of gene expression proﬁling is now
being evaluated in prospective studies. MINDACT
(Microarray In Node negative Disease may Avoid Che-
moTherapy), an ongoing three-part randomized trial of
6,000 patients with node-negative breast cancer, is com-
paring the efﬁcacy of selection of breast cancer patients for
adjuvant chemotherapy based on either clinical criteria or
the 70-gene microarray prognosis proﬁle [91]. In one part
of the trial, 3,500 node-negative, HR+ positive patients will
be randomized to receive either 7 years of letrozole or
2 years of tamoxifen followed by 5 years of letrozole. In
the US, the TAILORx Trial [92] is comparing hormone
therapy with or without combination chemotherapy as
adjuvant therapy for node-negative, ER+ breast cancer.
The objective of this randomized phase III trial is to
determine the best individual therapy using Oncotype DX
gene proﬁling.
One of the more recent advances in transcriptional
proﬁling addresses its potential application as an identiﬁ-
cation tool for ‘‘oncogenic pathway signatures’’ that could
be used to guide targeted therapy. Oncogenic pathway
signatures, developed in cell-line models, have been shown
to predict sensitivity to therapeutic agents in vitro [93].
This offers an opportunity to identify pathway-speciﬁc
drugs in endocrine therapy-resistant tumors and creates an
opportunity for the rational design of combination therapy
with letrozole. In addition to the RNA-based gene
expression proﬁling approach, high throughput analysis at
the DNA level, such as genome-wide microarray compar-
ative genomic hybridization (aCGH) and DNA sequencing,
has made it possible to decipher the genetic anomalies that
drive a particular tumor phenotype. The use of these
molecular approaches for biomarker development is still in
its infancy but is now feasible with recent advances in
genomic technologies.
Conclusions
Hormone-sensitive breast cancer can be regarded as a
chronic disease with a persistent risk of escape from
effective endocrine control. Activation of growth factor
signaling pathways has been implicated in progression of
HR+ breast cancer to an estrogen-independent phenotype
and the development of resistance to endocrine therapy,
particularly tamoxifen. It has been hypothesized that
combining endocrine therapy with targeted signal trans-
duction inhibitors may circumvent hormone-independent
signaling pathways, so that patients may experience pro-
longed disease control.
Letrozole is one of the most potent AIs. As such, it may
be more effective than tamoxifen for patients with tumor
proﬁles associated with a high risk of developing hormone
resistance (e.g., tumors with HER2 gene ampliﬁcation) and
represents an ideal combination partner for agents that
inhibit growth signaling pathways implicated in hormone
resistance. The efﬁcacy of letrozole is currently being
investigated with a variety of signal transduction inhibitors
with different mechanisms of action, including monoclonal
antibodies against HER family receptors, receptor tyrosine
kinase inhibitors, and downstream signaling pathway
inhibitors.
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new tool to predict risk of relapse in patients treated with
hormone therapy and chemotherapy. This approach will
help physicians to identify which patient will likely beneﬁt
from speciﬁc therapies, such as letrozole. Tailoring therapy
to individual patient proﬁles (clinical, histologic, patho-
logic, and genetic) will become more sophisticated in the
future, helping to maximize the beneﬁts of endocrine
therapy throughout the breast cancer continuum; letrozole
will undoubtedly become an integral part of the next gen-
eration of tailored combination regimens for the treatment
of breast cancer.
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